Blood Publishes Pre-Clinical Data on GlycoMimetics, Inc. Lead Compound in Sickle Cell Disease Model

GAITHERSBURG, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced that the journal Blood has published pre-clinical data on the company’s lead compound GMI-1070 in a model of sickle cell disease. The article, “GMI-1070, a novel pan-selectin antagonist, reverses acute vascular occlusions in sickle cell mice,” presents pre-clinical data supporting testing of GMI-1070 in clinical trials to treat patients with vaso-occlusive crisis of sickle cell disease. The article is accompanied by a commentary entitled “Mightier Than the Sickle Cell,” which discusses the biological mechanism involved in the activity of GMI-1070 in the sickle cell model.